This is the only comprehensive and up-to-date book on neurological PET. Its goal is to facilitate cooperation between PET experts, neuroscientists and clinicians. We review PET in neuroscience with particular emphasis on findings that indicate its potential for improving diagnosis and treatment in neurology and psychiatry. We want to improve the transfer of the huge scientific developments in brain PET into clinical care to produce tangible human benefit. We therefore focus on practical and potentially clinically relevant issues and identify solid ground as well as open questions. In addition,…mehr
This is the only comprehensive and up-to-date book on neurological PET. Its goal is to facilitate cooperation between PET experts, neuroscientists and clinicians. We review PET in neuroscience with particular emphasis on findings that indicate its potential for improving diagnosis and treatment in neurology and psychiatry. We want to improve the transfer of the huge scientific developments in brain PET into clinical care to produce tangible human benefit. We therefore focus on practical and potentially clinically relevant issues and identify solid ground as well as open questions. In addition, the book includes major chapters on the methodological background, including tracer physiology and kinetic modeling, and a comprehensive literature review. The book contains a CD-ROM with video clips and interactive navigation in 3D data sets that illustrate the information contained in PET images in major neurological diseases and its potential to improve diagnosis and neurosurgical planning in brain tumors.- Authors are all experts in the field; Herscovitch is head of PET Imaging at NIH.
- PET is becoming dominant technology for diagnosis in Neurology; books have not caught up. NeuroPET is ahead of the curve.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Karl Herholz, University of Cologne, Max-Planck-Institute for Neurological Research, Cologne, Germany / Peter Herscovitch, National Institutes of Health, Bethesda, MD, USA / W.-D. Heiss, University of Cologne, Max-Planck-Institute for Neurological Research, Cologne, Germany
Inhaltsangabe
1 Introduction.- 2 Clinical Studies.- 2.1 Dementia and Memory Disorders.- 2.1.1 Clinical and Research Issues.- 2.1.2 Alzheimer's Disease and Mild Cognitive Impairment.- 2.1.2.1 Cerebral Glucose Metabolism.- 2.1.2.2 Cholinergic Degeneration.- 2.1.2.3 Other Receptors and Transmitters.- 2.1.2.4 Amyloid Imaging.- 2.1.2.5 Activation Studies.- 2.1.3 Dementia with LewyBodies.- 2.1.4 Frontotemporal Dementia and Related Disorders.- 2.1.5 Vascular Dementia.- 2.1.6 Creutzfeldt-Iakob Disease.- 2.1.7 Other Memory Disorders.- 2.1.7.1 Hypoxic and Global Ischemic Brain Damage.- 2.1.7.2 Other Amnesic Syndromes.- 2.2 Movement Disorders.- 2.2.1 Idiopathic Parkinson Disease.- 2.2.1.1 Diagnostic Issues.- 2.2.1.2 Dopamine Synthesis.- 2.2.1.3 Dopamine Release and Turnover.- 2.2.1.4 Dopamine Transporters.- 2.2.1.5 Vesicular Monoamine Transporter.- 2.2.1.6 Dopamine Receptors.- 2.2.1.7 Mesocortical Dopaminergic Innervation.- 2.2.1.8 Other Transmitters.- 2.2.1.9 Resting Glucose Metabolism.- 2.2.1.10 Activation Studies.- 2.2.1.11 Familial PD.- 2.2.1.12 Disease Progression.- 2.2.1.13 Depression in PD.- 2.2.1.14 Improving and Understanding Treatment Effects.- 2.2.2 Multiple System Atrophy.- 2.2.2.1 Olivo-ponto-cerebellar Atrophy.- 2.2.2.2 Striatonigral Degeneration.- 2.2.2.3 Shy-Drager Syndrome.- 2.2.3 Other Neurodegenerative Disorders.- 2.2.3.1 Progressive Supranuclear Palsy.- 2.2.3.2 Corticobasal Degeneration.- 2.2.3.3 Disorders with Abnormal Deposition of Metals.- 2.2.3.4 Parkinsonism Attributable to Toxic and Inflammatory Brain Damage.- 2.2.3.5 Amyotrophic Lateral Sclerosis.- 2.2.3.6 Other Rare Disorders.- 2.2.4 Hyperkinetic Syndromes.- 2.2.4.1 Huntington's Chorea (Huntington Disease).- 2.2.4.2 Other Choreic Disorders.- 2.2.4.3 Restless LegsSyndrome.- 2.2.4.4 Essential and Orthostatic Tremor.- 2.2.4.5 Tourette Syndrome.- 2.2.5 Dystonia and Related Disorders.- 2.2.5.1 Idiopathic Dystonia and Torticollis.- 2.2.5.2 DOPA-responsiveDystonia.- 2.2.5.3 Dystonia Attributable to Localized Lesions or Degeneration.- 2.2.6 Ataxia.- 2.2.6.1 Spinocerebellar Ataxia.- 2.2.6.2 Friedreich's Ataxia.- 2.2.6.3 Other Ataxias.- 2.3 Brain Tumors.- 2.3.1 Biological Grading.- 2.3.1.1 Glucose Consumption.- 2.3.1.2 Amino Acid Uptake.- 2.3.1.3 Nucleoside Uptake.- 2.3.2 PET-Guided Stereotactic Biopsy.- 2.3.3 Differentiation Between Recurrent Tumor and Radiation Necrosis.- 2.3.4 Monitoring of Therapy.- 2.3.5 Identification of Hypoxic Tumor Tissue.- 2.3.6 Improving and Planning Therapy.- 2.3.7 New Therapies.- 2.3.8 Other Tracers for Brain Tumors.- 2.3.9 Extracranial Tumors of the Nervous System.- 2.3.10 Detection of Primary Tumors.- 2.3.11 Activation Studies.- 2.3.11.1 Motor Function.- 2.3.11.2 Language.- 2.4 Cerebrovascular Disease.- 2.4.1 Ischemic Stroke.- 2.4.2 Intracerebral and Subdural Hemorrhage.- 2.4.3 Subarachnoid Hemorrhage.- 2.4.4 Remote Effects (Diaschisis).- 2.4.5 Chronic Hemodynamic Impairment.- 2.4.6 Moyamoya Disease.- 2.4.7 Genetic Disorders (MELAS, CADASIL).- 2.4.8 Brain Function and RecoveryAfter Stroke.- 2.4.8.1 Aphasia.- 2.4.8.2 Motor Function.- 2.4.8.3 Neglect.- 2.5 Epilepsy.- 2.5.1 Localization of Epileptogenic Foci.- 2.5.1.1 Temporal Lobe Epilepsy.- 2.5.1.2 Neocortical Focal Epilepsy.- 2.5.1.3 Ictal Studies.- 2.5.1.4 GABA-A and Benzodiazepine Receptors.- 2.5.1.5 Other Transmitters and Receptors.- 2.5.1.6 Inflammatory Lesions and Glial Reaction.- 2.5.2 Progression of Epileptic Lesions.- 2.5.3 Prediction of Surgical Outcome.- 2.5.4 Malformations of Cortical Development.- 2.5.5 Childhood Epileptic Syndromes.- 2.5.6 Language Dominance.- 2.5.7 Effects of Surgical Intervention and Medical Treatment.- 2.5.8 Generalized Epilepsy.- 2.6 Other Neurological Disorders.- 2.6.1 Traumatic Brain Injury.- 2.6.2 Persistent VegetativeState.- 2.6.3 Perinatal Brain Damage.- 2.6.4 Inflammatory Disease.- 2.6.5 Pain.- 2.6.6 Migraine and Cluster Headache.- 2.6.7 Narcolepsy.- 2.6.8 Hypoparathyroidism (Fahr's Disease).- 2.6.9 Systemic Inherited Metabolic Disorders.- 2.7 Psychiatric Disord
1 Introduction.- 2 Clinical Studies.- 2.1 Dementia and Memory Disorders.- 2.1.1 Clinical and Research Issues.- 2.1.2 Alzheimer's Disease and Mild Cognitive Impairment.- 2.1.2.1 Cerebral Glucose Metabolism.- 2.1.2.2 Cholinergic Degeneration.- 2.1.2.3 Other Receptors and Transmitters.- 2.1.2.4 Amyloid Imaging.- 2.1.2.5 Activation Studies.- 2.1.3 Dementia with LewyBodies.- 2.1.4 Frontotemporal Dementia and Related Disorders.- 2.1.5 Vascular Dementia.- 2.1.6 Creutzfeldt-Iakob Disease.- 2.1.7 Other Memory Disorders.- 2.1.7.1 Hypoxic and Global Ischemic Brain Damage.- 2.1.7.2 Other Amnesic Syndromes.- 2.2 Movement Disorders.- 2.2.1 Idiopathic Parkinson Disease.- 2.2.1.1 Diagnostic Issues.- 2.2.1.2 Dopamine Synthesis.- 2.2.1.3 Dopamine Release and Turnover.- 2.2.1.4 Dopamine Transporters.- 2.2.1.5 Vesicular Monoamine Transporter.- 2.2.1.6 Dopamine Receptors.- 2.2.1.7 Mesocortical Dopaminergic Innervation.- 2.2.1.8 Other Transmitters.- 2.2.1.9 Resting Glucose Metabolism.- 2.2.1.10 Activation Studies.- 2.2.1.11 Familial PD.- 2.2.1.12 Disease Progression.- 2.2.1.13 Depression in PD.- 2.2.1.14 Improving and Understanding Treatment Effects.- 2.2.2 Multiple System Atrophy.- 2.2.2.1 Olivo-ponto-cerebellar Atrophy.- 2.2.2.2 Striatonigral Degeneration.- 2.2.2.3 Shy-Drager Syndrome.- 2.2.3 Other Neurodegenerative Disorders.- 2.2.3.1 Progressive Supranuclear Palsy.- 2.2.3.2 Corticobasal Degeneration.- 2.2.3.3 Disorders with Abnormal Deposition of Metals.- 2.2.3.4 Parkinsonism Attributable to Toxic and Inflammatory Brain Damage.- 2.2.3.5 Amyotrophic Lateral Sclerosis.- 2.2.3.6 Other Rare Disorders.- 2.2.4 Hyperkinetic Syndromes.- 2.2.4.1 Huntington's Chorea (Huntington Disease).- 2.2.4.2 Other Choreic Disorders.- 2.2.4.3 Restless LegsSyndrome.- 2.2.4.4 Essential and Orthostatic Tremor.- 2.2.4.5 Tourette Syndrome.- 2.2.5 Dystonia and Related Disorders.- 2.2.5.1 Idiopathic Dystonia and Torticollis.- 2.2.5.2 DOPA-responsiveDystonia.- 2.2.5.3 Dystonia Attributable to Localized Lesions or Degeneration.- 2.2.6 Ataxia.- 2.2.6.1 Spinocerebellar Ataxia.- 2.2.6.2 Friedreich's Ataxia.- 2.2.6.3 Other Ataxias.- 2.3 Brain Tumors.- 2.3.1 Biological Grading.- 2.3.1.1 Glucose Consumption.- 2.3.1.2 Amino Acid Uptake.- 2.3.1.3 Nucleoside Uptake.- 2.3.2 PET-Guided Stereotactic Biopsy.- 2.3.3 Differentiation Between Recurrent Tumor and Radiation Necrosis.- 2.3.4 Monitoring of Therapy.- 2.3.5 Identification of Hypoxic Tumor Tissue.- 2.3.6 Improving and Planning Therapy.- 2.3.7 New Therapies.- 2.3.8 Other Tracers for Brain Tumors.- 2.3.9 Extracranial Tumors of the Nervous System.- 2.3.10 Detection of Primary Tumors.- 2.3.11 Activation Studies.- 2.3.11.1 Motor Function.- 2.3.11.2 Language.- 2.4 Cerebrovascular Disease.- 2.4.1 Ischemic Stroke.- 2.4.2 Intracerebral and Subdural Hemorrhage.- 2.4.3 Subarachnoid Hemorrhage.- 2.4.4 Remote Effects (Diaschisis).- 2.4.5 Chronic Hemodynamic Impairment.- 2.4.6 Moyamoya Disease.- 2.4.7 Genetic Disorders (MELAS, CADASIL).- 2.4.8 Brain Function and RecoveryAfter Stroke.- 2.4.8.1 Aphasia.- 2.4.8.2 Motor Function.- 2.4.8.3 Neglect.- 2.5 Epilepsy.- 2.5.1 Localization of Epileptogenic Foci.- 2.5.1.1 Temporal Lobe Epilepsy.- 2.5.1.2 Neocortical Focal Epilepsy.- 2.5.1.3 Ictal Studies.- 2.5.1.4 GABA-A and Benzodiazepine Receptors.- 2.5.1.5 Other Transmitters and Receptors.- 2.5.1.6 Inflammatory Lesions and Glial Reaction.- 2.5.2 Progression of Epileptic Lesions.- 2.5.3 Prediction of Surgical Outcome.- 2.5.4 Malformations of Cortical Development.- 2.5.5 Childhood Epileptic Syndromes.- 2.5.6 Language Dominance.- 2.5.7 Effects of Surgical Intervention and Medical Treatment.- 2.5.8 Generalized Epilepsy.- 2.6 Other Neurological Disorders.- 2.6.1 Traumatic Brain Injury.- 2.6.2 Persistent VegetativeState.- 2.6.3 Perinatal Brain Damage.- 2.6.4 Inflammatory Disease.- 2.6.5 Pain.- 2.6.6 Migraine and Cluster Headache.- 2.6.7 Narcolepsy.- 2.6.8 Hypoparathyroidism (Fahr's Disease).- 2.6.9 Systemic Inherited Metabolic Disorders.- 2.7 Psychiatric Disord
Rezensionen
From the reviews:
This is the most comprehensive book written to date which reviews applications of PET in brain disorders, measurements of regional brain function, molecular imaging and PET methodology.
Rarer states are reviewed as well as those not normally considered as presenting with functional brain lesions such as pain and migraine.
For those with clinical PET facilities, this book will indentify how this technology could be exploited for the care of brain disorder patients.
RAD Magazine, December, 2005
"This book is by world authorities in both the methodology of positron emission tomography (PET) and its applications in clinical neurology. According to the authors, it is intended to 'guide both nuclear medicine specialists and also neurologists and psychiatrists in the use of PET'; I assume they also meant to include neurosurgeons, neurophysiologists and clinical neuroscientists. ... This book is unique in its kind. ... it will prove an invaluable source of historical information about one of the major revolutions in understanding brain diseases." (J. -C. Baron, Acta Neurochirurgica, Vol. 147, 2005)
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
